专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070154911A1 REGULATORY PROTEIN PKE#83 FROM HUMAN KERATINOCYTES 审中-公开
标题翻译：人类KERATINOCYTES的调节蛋白PKE＃83
公开(公告)号：US20070154911A1
公开(公告)日：2007-07-05
申请号：US11566115
申请日：2006-12-01
申请人： Michael Kramer , Michael Bechtel , Jeanette Reinartz , Birgit Schaefer , Reinhard Wallich
发明人： Michael Kramer , Michael Bechtel , Jeanette Reinartz , Birgit Schaefer , Reinhard Wallich
IPC分类号： C12Q1/68 , C07H21/04 , C12P21/06 , C07K14/78
CPC分类号： C07K16/18 , C07K14/4702
摘要： The invention relates to an isolated polypeptide which is the same as or similar to (i.e., has the same function and effect as) a protein which occurs naturally in human keratinocytes and is more strongly expressed when the keratinocytes are in their activated state. The invention also relates to an isolated nucleic acid which codes a polypeptide or protein of this type that is typical for human keratinocytes and to the use of said polypeptide and said nucleic acid for detection, especially diagnostic purposes and/or for therapeutic purposes or the use of reagents, especially recombinant vector molecules and antibodies, against molecules of this type. The inventive protein has the amino acid sequence shown in sequence protocol SEQ ID NO:3 or an allele or derivative of this amino acid sequence produced therefrom by amino acid substitution, deletion, insertion, or inversion, and the inventive nucleic acid has either the amino acid sequence shown in sequence protocol SEQ ID NO:1 or a nucleotide sequence complementary thereto or a partial sequence of one of these two nucleotide sequences or a nucleotide sequence which is completely or partially hybridizable one of these two nucleotide sequences.
摘要翻译：本发明涉及与角质形成细胞处于其活化状态时天然存在的蛋白质相同或相似（即具有与之相同的功能和作用）的分离多肽。本发明还涉及编码这种类型的多肽或蛋白质的分离的核酸，其是人角质形成细胞的典型特征，以及使用所述多肽和所述核酸进行检测，特别是诊断目的和/或用于治疗目的或使用的试剂，特别是重组载体分子和抗体。本发明的蛋白质具有序列方案SEQ ID NO：3所示的氨基酸序列或通过氨基酸取代，缺失，插入或倒位从其产生的该氨基酸序列的等位基因或衍生物，并且本发明的核酸具有氨基酸序列方案SEQ ID NO：1所示的酸序列或其互补的核苷酸序列或这两个核苷酸序列之一的部分序列或这两个核苷酸序列之一完全或部分杂交的核苷酸序列。

2. 发明授权

US6113914A Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines 失效
标题翻译： Osp一种布氏疏螺旋体亚群的蛋白质，编码基因和疫苗
公开(公告)号：US6113914A
公开(公告)日：2000-09-05
申请号：US193159
申请日：1994-07-05
申请人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
发明人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
IPC分类号： A61K38/00 , A61K39/00 , A61K39/02 , A61P31/04 , C07K14/11 , C07K14/20 , C07K16/00 , C07K16/12 , C07K19/00 , C12N1/20 , C12N15/00 , C12N15/09 , C12N15/31 , C12N15/32 , C12N15/44 , C12N15/62 , C12P21/02 , C12P21/08 , C12Q1/68 , C12R1/01 , C12R1/19 , A61K39/116 , G01N33/554
CPC分类号： C07K16/1207 , C07K14/005 , C07K14/20 , C12Q1/689 , C12R1/01 , A61K38/00 , A61K39/00 , C07K2319/40 , C12N2760/16022 , Y10S530/806 , Y10S530/82 , Y10S530/825
摘要： The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
摘要翻译： PCT No.PCT / EP92 / 01827 Sec。 371日期：1994年7月5日 102（e）日期1994年7月5日PCT提交1992年8月11日PCT公布。公开号WO93 / 04175 日期1993年3月4日本发明涉及由其衍生的新型疏螺旋体和OspA抗原。这些抗原与已知的OspA显示出很小的同源性，因此可用作疫苗和诊断试剂。还公开了基于来自不同Borrelia组的OspA的多组分疫苗。

3. 发明授权

US5942236A Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines 失效
标题翻译： Osp一种布氏疏螺旋体亚群的蛋白质，编码基因和疫苗
公开(公告)号：US5942236A
公开(公告)日：1999-08-24
申请号：US441857
申请日：1995-05-16
申请人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
发明人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
IPC分类号： A61K38/00 , A61K39/00 , A61K39/02 , A61P31/04 , C07K14/11 , C07K14/20 , C07K16/00 , C07K16/12 , C07K19/00 , C12N1/20 , C12N15/00 , C12N15/09 , C12N15/31 , C12N15/32 , C12N15/44 , C12N15/62 , C12P21/02 , C12P21/08 , C12Q1/68 , C12R1/01 , C12R1/19 , C07K14/00
CPC分类号： C07K16/1207 , C07K14/005 , C07K14/20 , C12Q1/689 , C12R1/01 , A61K38/00 , A61K39/00 , C07K2319/40 , C12N2760/16022 , Y10S530/806 , Y10S530/82 , Y10S530/825
摘要： The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
摘要翻译：本发明涉及疏螺旋体和由其衍生的OspA抗原。这些抗原与已知的OspA显示出很小的同源性，因此可用作疫苗和诊断试剂。还公开了基于来自不同Borrelia组的OspA的多组分疫苗。

4. 发明授权

US06676942B1 Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines 失效
标题翻译： Osp是布氏疏螺旋体亚群的蛋白质，编码基因和疫苗
公开(公告)号：US06676942B1
公开(公告)日：2004-01-13
申请号：US09283646
申请日：1999-04-01
申请人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
发明人： Yves Lobet , Markus Simon , Ulrich Schaible , Reinhard Wallich , Michael Kramer
IPC分类号： A61K3902
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07K14/20 , C07K16/1207 , C07K2319/00 , C12N2760/16022 , C12Q1/689 , C12R1/01 , Y02A50/401 , Y02A50/57
摘要： The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
摘要翻译：本发明涉及新型的疏螺旋体和由其衍生的OspA抗原。这些抗原与已知的OspA几乎没有同源性，因此可用作疫苗和诊断试剂。还公开了基于来自不同Borrelia组的OspA的多组分疫苗。

5. 发明授权

US06761891B1 Medicament for treating a manifested lyme disease 失效
标题翻译：用于治疗表现为淋巴液病的药物
公开(公告)号：US06761891B1
公开(公告)日：2004-07-13
申请号：US09508096
申请日：2000-07-06
申请人： Markus M. Simon , Weimin Zhong , Reinhard Wallich , Michael D. Kramer
发明人： Markus M. Simon , Weimin Zhong , Reinhard Wallich , Michael D. Kramer
IPC分类号： A61K3902
CPC分类号： C07K14/20 , A61K38/00 , A61K39/00 , C07K16/1207 , C07K2319/00 , Y02A50/401
摘要： A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of B. burgdorferi, preferably an antibody which is specific for the 24 kDa antigen (OspC) of B. burgdorferi having the sequence shown in SEQ ID NO.2.
摘要翻译：用于治疗莱姆病的药物组合物含有作为活性剂的抗体，其对布氏疏螺旋体的24kDa抗原（OspC）是特异性的，优选地是对具有Burgdorferi的24kDa抗原（OspC）特异性的抗体序列如SEQ ID NO.2所示。

6. 发明申请

US20110236455A1 Novel Regulators of the Innate Immune System 审中-公开
标题翻译：先天免疫系统的新型调节器
公开(公告)号：US20110236455A1
公开(公告)日：2011-09-29
申请号：US13121029
申请日：2009-09-28
申请人： Peter Zipfel , Christina Skerka , Reinhard Wallich
发明人： Peter Zipfel , Christina Skerka , Reinhard Wallich
IPC分类号： A61K38/17 , C07K14/46 , A61M31/00 , C07K16/18 , C12N5/16 , G01N33/577 , A61P29/00 , A61L33/12
CPC分类号： A61L27/54 , A61K38/00 , A61L27/22 , A61L2300/252 , A61L2300/256 , A61L2300/41 , A61L2300/434 , C07K14/472 , C07K14/811 , C07K16/18 , G01N33/92 , G01N2800/347
摘要： The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H. In a further aspect, the present invention focuses on providing monoclonal antibodies which specifically detect CFHR proteins, and on the use thereof in methods of determining CFHR in body fluids. These methods are particularly suitable for diagnosing inflammatory diseases.
摘要翻译：本发明涉及先天免疫系统，特别是补体系统的新型调节剂的鉴定。更具体地说，本发明涉及具体的C5转化酶抑制剂。这些新型抑制剂特别适用于治疗涉及补体系统的炎性疾病。在第一方面，本发明着重于CFHR蛋白及其功能片段或其功能衍生物用于预防炎症反应的用途。在另一方面，本发明着重于所述CFHR蛋白在移植和透析期间灭活补体活化以及与血液或体液（特别是植入物）接触的涂覆装置的用途。本发明还提供了包含与功能性因子H组合的功能性CFHR蛋白质的药物组合物。在另一方面，本发明着重于提供特异性检测CFHR蛋白质的单克隆抗体，以及在确定体液中CFHR的方法中的用途。这些方法特别适用于诊断炎性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式